Page last updated: 2024-09-03

1-aminoindan and Parkinson Disease

1-aminoindan has been researched along with Parkinson Disease in 1 studies

*Parkinson Disease: A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75) [MeSH]

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Balogh, B; Chai, CL; Chua, YY; Deme, R; Gölöncsér, F; Ho, HK; Huleatt, PB; Khoo, ML; Liew, RS; Magyar, K; Mátyus, P; Sheela, DP; Sperlágh, B; Tan, TW1

Other Studies

1 other study(ies) available for 1-aminoindan and Parkinson Disease

ArticleYear
Novel arylalkenylpropargylamines as neuroprotective, potent, and selective monoamine oxidase B inhibitors for the treatment of Parkinson's disease.
    Journal of medicinal chemistry, 2015, Feb-12, Volume: 58, Issue:3

    Topics: Animals; Cell Survival; Cells, Cultured; Dose-Response Relationship, Drug; Humans; Mice; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Neuroprotective Agents; Pargyline; Parkinson Disease; PC12 Cells; Propylamines; Rats; Structure-Activity Relationship

2015